Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab

by Sarah Fischer, Sarah Cohnen, Entcho Klenske, Heike Schmitt, Francesco Vitali, Simon Hirschmann, Andreas Ramming, Sebastian Zundler, Timo Rath, Sabine Krebs, Frank Dörje, Wolfgang Uter, Daniel Nagore, Sebastian Meyer, Markus F. Neurath, Raja Atreya
Published 2021-01-01